Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with Francesca Pesenti and Nicolai Bleskie (all corporate/m&a). TargImmune Therapeutics focuses on drug development using novel targeted immunotherapies. The principal […]
Meyer Burger successfully placed newly issued shares raising gross proceeds of CHF 80 million and EUR 145 million green guaranteed senior unsecured convertible
Dec Group, a global provider of contained powder handling systems has acquired the Extract Technology business from U.S- based Wabash National Corporation, a company listed on the New York Stock Exchange. Extract Technology is
Zurich based generics company, Fairmed Healthcare, which is majority owned by Strides Pharma Global, announced that it has raised €10 million in senior secured financing from Duke Royalty. Urbach Law acted as transaction counsel for
Raiffeisen Schweiz Genossenschaft, a Swiss systemically relevant bank, issued AT1 Bonds in the total amount of CHF 300 million. With a base tranche of CHF 200 million on 31 March 2021 and a first reopening of CHF 100 million on 1
Québec issued CHF 250 million Bonds. Deutsche Bank London Branch, acting through Deutsche Bank Zurich Branch acted as Lead Manager. The Bonds will be listed on the SIX Swiss Exchange. Homburger advised Deutsche Bank Zurich
Gaz Finance issued Chf 500 m Loan Participation Notes on June 30, 2021. The Loan Participation Notes were used to fund a loan by the Issuer to Public Joint Stock Company Gazprom. UBS acted as lead manager, together
Pestalozzi advises global institutional investors in connection with up to $ 44,000,000 equity linked investment in WISeKey International Holding listed at SIX Swiss Exchange and with ADS traded at Nasdaq. The investment is structured in two convertible
Dermavant Sciences, a clinically focused biopharmaceutical company dedicated to developing and commercializing innovative therapies in the field of immune dermatology, has signed a $160 million revenue interest purchase and sale agreement with three participants for its
Anapaya Systems, the commercial provider of SCION technology, has secured CHF 6.8 million in funding with lead investor SIX Fintech Ventures, the corporate venture arm of SIX. Bär & Karrer acted as legal advisor to
